GeneNews company
%20.jpg)
GeneNewsâ„¢ is a molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic tests for early disease detection, determining the stage of disease and monitoring its progression, treatment or recurrence. Tests based on the company's Sentinel Principleâ„¢ are being developed in the areas of cancer, cardiovascular diseases, psychiatric disorders, central nervous system diseases and arthritis. The company's lead product in its Sentry line of blood tests is ColonSentry, a test for colorectal cancer screening that is commercially available in Ontario.
Total Funding:
$51.9M
Headquarters:
Richmond Hill, Ontario, Canada
Funding Status:
IPO
Employee Number:
11-50
Estimated Revenue:
Less than $1M
Last Funding Type:
Venture - Series Unknown
Technology:
P4 Medicine
Investor Type:
For Profit
Investors Number:
28
Founded Date:
1998-01-01
Industry:
Biotechnology, Health Care, Science and Engineering